65872-41-5Relevant articles and documents
Antibiotic-improved cefmenoxime hydrochloride synthesis process
-
Paragraph 0045, (2021/02/06)
The invention discloses an antibiotic-improved cefmenoxime hydrochloride synthesis process, which comprises the following steps: step 1, preparation of 1-methyl-5-sulfydryl-1H-tetrazole, step 2, preparation of 2-(2-amino-4-azolyl)-2(Z)-methoxyimino ethyl acetate; step 3, preparation of 2-(2-amino-4-thiazolyl)-2-(Z)-methoxyimino acetic acid; step 4, preparation of 2-(2-amino-4-thiazolyl)-2-(Z)-methoxyimino acetic acid-2-benzothiazole thioester; step 5, preparation of 7-amino-3-(1-methyl-1H-tetrazole-5-thiomethyl)cephalosporanic acid hydrochloride (7-ACA-MMT. HC1); and step 6, preparation of cefmenoxime hydrochloride; domestic raw materials are adopted, the raw materials are cheap and easy to obtain in the synthesis route, the synthesis cost is reduced, and synthesis is improved; the improved process has the advantages of low raw material cost, simplicity in operation and suitability for industrial production.
Process for producing chloroacetylaminothiazoleacetic acid derivatives
-
, (2008/06/13)
The present invention relates to a simple process for producing 2-aminothiazoleacetic acid derivatives useful as intermediates for producing cephalosporin-type antibiotics. The process for producing chloroacetylaminothiazoleacetic acid derivatives represented by the following formula (II) ???wherein R1 is a protection group for the hydroxyl group,comprises reacting aminothiazoleacetic acid derivatives represented by the following formula (I) ???wherein R1 is a protection group for the hydroxyl group,with a chloroacetylating agent.
Triazolo-pyrimidine intermediates
-
, (2008/06/13)
There are disclosed a β-lactam compound represented by the formula (I): STR1 wherein R1 represents an acyl group; M represents a hydrogen atom, a protective group of an eliminatable group which is easily hydrolyzable in a human body; B represents a group represented by the formula (b): STR2 where at least one of R2, R3 and R9 represent a group represented by the formula: -A-OR4 where R4 represents a hydrogen or a lower alkyl group; and A represents a straight or branched alkylene group having 1 to 6 carbon atoms; and a remaining group or groups are each independently a hydrogen atom; a cyano group; a lower alkyl group which may be substituted by a halogen atom; a carbamoyl group which may be substituted by a lower alkyl group; a cycloalkyl group; or a carboxyl group which may be substituted by a protective group of an eliminatable group which is easily hydrolyzable in a human body, and also when R9 is -A-OR4, R2 and R3 may be combined with each other to form an alkylene group having 3 to 4 carbon atoms; and Z represents a nitrogen atom or a group represented by the formula: C-R10 where R10 represents a hydrogen atom, a carboxyl group or a lower alkyl group which may be substituted by a hydroxy group or a lower alkoxy group, or its pharmaceutically acceptable salt, and a process for preparing the same, an intermediate for synthesis of the same and a medicinal composition for bacterially infectious disease therapy containing the same.